Glenmark Pharmaceuticals said that its US-based subsidiary has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) SingleDose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials.

The launched product is the generic version of Validus Pharmaceuticals’ Bumex Injection, 0.25 mg/mL.

Bumex is indicated for the treatment of swelling and high blood pressure.

As per IQVIA sales data for the 12 months ending November 2022, the Bumex Injection, 0.25 mg/mL market had annual sales of around $16.5 million.

Vijay Raghavan — Glenmark Pharmaceuticals Senior Vice President, Business Development Portfolio, Product Launch & Strategy said: “We are very pleased to bring to market a lower cost alternative to Bumex Injection, 0.25 mg/mL.

“This launch of Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials affirms our commitment to Glenmark’s continued focus on institutional business.”

The current portfolio of Glenmark Pharmaceuticals features 179 products with US Food and Drug Administration (FDA) authorization for distribution in the US marketplace and 46 abbreviated new drug applications (ANDAs) awaiting approval from the regulator.

  blood pressure, Bumetanide, Bumex, Glenmark Pharmaceuticals, High Blood Pressure, Swelling, USA, Validus Pharmaceuticals, Vijay Raghavan